Among adults with T2DM and nephrotic-range proteinuria, SGLT2i versus DPP4i was associated with lower long-term risks of ESKD and all-cause mortality and no clear differences in cardiovascular or safety outcomes were observed. These real-world observational findings support a potential kidney-protective role of SGLT2i in this very high-risk group and complement existing randomized trial data, but dedicated randomized trials in patients with nephrotic-range proteinuria remain necessary.
Chen et al. (Mon,) studied this question.